ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PYC Physiomics Plc

1.50
-0.05 (-3.23%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -3.23% 1.50 1.40 1.60 1.50 1.50 1.50 242,798 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 597k -477k -0.0035 -4.29 2.03M

Physiomics PLC Share Price Movement (0132Y)

30/11/2017 1:38pm

UK Regulatory


Physiomics (LSE:PYC)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Physiomics Charts.

TIDMPYC

RNS Number : 0132Y

Physiomics PLC

30 November 2017

Physiomics plc

("Physiomics") or ("the Company")

Share Price Movement

Following the movement in the Physiomics share price today the Company would like to draw investors' attention to its RNS of the 28(th) of November in which the Company announced the signing of a Master Services Agreement ("Agreement") with Merck KGaA whose minimum value in the first twelve months of the contract is EUR500,000 (equivalent to around 60% of our net operating expenses for the financial year ended 30 June 2017). The Company would like to confirm that this represents the expected value of the contract in the first twelve months and that there is no guarantee that it will be higher than this. The Company would also like to confirm that the contract envisages a multi-year agreement with no specific term and that the annual value of services provided under the contract after the first year is not guaranteed. As previously stated, the Company sees this as a significant external validation of its technology platform as well as the cementing of the relationship with a significant big pharma client.

The Company also notes that the 12 projects completed with Merck KGaA since 2012, were in the ordinary course of business. All except two were completed in prior financial periods and their average value was around GBP30k.

By order of the Board of Physiomics plc.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

This information is provided by RNS

The company news service from the London Stock Exchange

END

SPMLLFVVLRLIVID

(END) Dow Jones Newswires

November 30, 2017 08:38 ET (13:38 GMT)

1 Year Physiomics Chart

1 Year Physiomics Chart

1 Month Physiomics Chart

1 Month Physiomics Chart

Your Recent History

Delayed Upgrade Clock